Bristol Myers Squibb-Pfizer Alliance Presents results from ATHENS Retrospective Observational Study Assessing Real-World Clinical Impact Of Switching Or Continuing Eliquis Or Rivaroxaban Presented At The European Society Of Cardiology Congress 2023
Portfolio Pulse from Happy Mohamed
The Bristol Myers Squibb-Pfizer Alliance presented results from a retrospective study at the European Society of Cardiology Congress 2023. The study showed that switching from Eliquis to rivaroxaban in Non-Valvular Atrial Fibrillation patients was associated with a higher risk of stroke and major bleeding than those who continued Eliquis. The study used real-world data from 2013 to 2021, and found that switching from rivaroxaban to Eliquis was associated with a similar risk of stroke and a lower risk of major bleeding compared to those who continued rivaroxaban.
August 25, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The study results may impact Bristol Myers Squibb's Eliquis sales, as it shows higher risks associated with switching from Eliquis to rivaroxaban.
The study results showing higher risks associated with switching from Eliquis to rivaroxaban may discourage doctors from recommending the switch, potentially impacting Bristol Myers Squibb's sales of Eliquis.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The study results may impact Pfizer's rivaroxaban sales, as it shows higher risks associated with switching from Eliquis to rivaroxaban.
The study results showing higher risks associated with switching from Eliquis to rivaroxaban may discourage doctors from recommending the switch, potentially impacting Pfizer's sales of rivaroxaban.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100